Clinical Trials Logo

ROS1 Proto Oncogene clinical trials

View clinical trials related to ROS1 Proto Oncogene.

Filter by:
  • None
  • Page 1

NCT ID: NCT01945021 Completed - Clinical trials for Non Small Cell Lung Cancer

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Start date: September 30, 2013
Phase: Phase 2
Study type: Interventional

To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a ROS1 positive gene mutation (translocation or inversion) and confirmed negative for an ALK mutation